AR028914A1 - 2-guanidino-4-aril-quinazolinas como inhibidores de nhe-3 - Google Patents

2-guanidino-4-aril-quinazolinas como inhibidores de nhe-3

Info

Publication number
AR028914A1
AR028914A1 ARP010101808A ARP010101808A AR028914A1 AR 028914 A1 AR028914 A1 AR 028914A1 AR P010101808 A ARP010101808 A AR P010101808A AR P010101808 A ARP010101808 A AR P010101808A AR 028914 A1 AR028914 A1 AR 028914A1
Authority
AR
Argentina
Prior art keywords
nhe
inhibitors
quinazolinas
aril
guanidino
Prior art date
Application number
ARP010101808A
Other languages
English (en)
Inventor
Gericke Rolf Dr
Beier Rolf Dr
Wilm Claudia Dr
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of AR028914A1 publication Critical patent/AR028914A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

Compuestos de la formula (1) donde Ar es un fenilo o naftilo insustituido o monosustituido por R3, R1, R2 es, independientemente entre sí, H, A, OA o CF3, R3 es A, OA, Hal o CF3, A es alquilo C1-6, Hal es F, Cl, Br o I y sus sales y solvatos fisiologicamente inofensivos como inhibidores NHE-3. También son objetos de la presente el uso para preparar medicamentos y preparacion farmacéutica.
ARP010101808A 2000-04-18 2001-04-18 2-guanidino-4-aril-quinazolinas como inhibidores de nhe-3 AR028914A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10019062A DE10019062A1 (de) 2000-04-18 2000-04-18 2-Guanidino-4-aryl-chinazoline als NHE-3 Inhibitoren

Publications (1)

Publication Number Publication Date
AR028914A1 true AR028914A1 (es) 2003-05-28

Family

ID=7639090

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010101808A AR028914A1 (es) 2000-04-18 2001-04-18 2-guanidino-4-aril-quinazolinas como inhibidores de nhe-3

Country Status (18)

Country Link
US (1) US20040224965A1 (es)
EP (1) EP1274691A1 (es)
JP (1) JP2004501082A (es)
KR (1) KR20030011789A (es)
CN (1) CN1422260A (es)
AR (1) AR028914A1 (es)
AU (1) AU2001293373A1 (es)
BR (1) BR0109867A (es)
CA (1) CA2406161A1 (es)
DE (1) DE10019062A1 (es)
HU (1) HUP0300909A3 (es)
MX (1) MXPA02010264A (es)
NO (1) NO20024997D0 (es)
PL (1) PL356559A1 (es)
RU (1) RU2002130246A (es)
SK (1) SK13472002A3 (es)
WO (1) WO2001079186A1 (es)
ZA (1) ZA200209274B (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10043667A1 (de) * 2000-09-05 2002-03-14 Merck Patent Gmbh 2-Guanidino-4-aryl-chinazoline
EP1453810B1 (de) * 2001-12-05 2009-03-18 Sanofi-Aventis Deutschland GmbH Substituierte 4-phenyltetrahydroisochinoline, verfahren zu ihrer herstellung, ihre verwendung als medikament, sowie sie enthaltendes medikament
US6911453B2 (en) 2001-12-05 2005-06-28 Aventis Pharma Deutschland Gmbh Substituted 4-phenyltetrahydroisoquinolinium, process for their preparation, their use as a medicament, and medicament containing them
DE10161767A1 (de) * 2001-12-15 2003-06-26 Merck Patent Gmbh 2-Guanidino-4-heterocyclyl-chinazoline
US20030187045A1 (en) 2001-12-21 2003-10-02 Uwe Heinelt Substituted imidazolidines, process for their preparation, and their use as a medicament or diagnostic
DE10163239A1 (de) * 2001-12-21 2003-07-10 Aventis Pharma Gmbh Substituierte Imidazolidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie enthaltendes Medikament
US6703405B2 (en) 2001-12-22 2004-03-09 Aventis Pharma Deutschland Gmbh Substituted 4-phenyltetrahydroisoquinolinium salts, process for their preparation, their use as a medicament, and medicament containing them
DE10163914A1 (de) * 2001-12-22 2003-07-03 Aventis Pharma Gmbh Substituierte 4-Phenyltetrahydroisochinolinium-Salze, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament
DE10163992A1 (de) * 2001-12-24 2003-07-03 Merck Patent Gmbh 4-Aryl-chinazoline
US7049333B2 (en) * 2002-06-04 2006-05-23 Sanofi-Aventis Deutschland Gmbh Substituted thiophenes: compositions, processes of making, and uses in disease treatment and diagnosis
DE10304374A1 (de) 2003-02-04 2004-08-05 Aventis Pharma Deutschland Gmbh Neue substituierte 2-Aminoimidazole, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
US20050054705A1 (en) 2003-02-04 2005-03-10 Aventis Pharma Deutschland Gmbh N-substituted (benzoimidazol-2-yl) phenylamines, process for their preparation, their use as medicament or diagnostic aid, and medicament comprising them
DE10341240A1 (de) 2003-09-08 2005-04-07 Aventis Pharma Deutschland Gmbh Substituierte Thienoimidazole, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE102005001411A1 (de) 2005-01-12 2006-07-27 Sanofi-Aventis Deutschland Gmbh Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament
DE102005044817A1 (de) * 2005-09-20 2007-03-22 Sanofi-Aventis Deutschland Gmbh Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament
WO2009006066A2 (en) 2007-06-28 2009-01-08 Sanofi-Aventis U.S. Llc Process for the preparation of benzimidazol thienylamine compounds and intermediates thereof
CN102203059B (zh) 2008-09-02 2015-05-06 赛诺菲-安万特 取代的氨基茚满及其类似物以及其医药用途
PL2384318T3 (pl) 2008-12-31 2018-04-30 Ardelyx, Inc. Związki i sposoby inhibicji mediowanego przez NHE antyportu w leczeniu zaburzeń związanych z retencją płynów lub nadmiarem soli i chorób przewodu pokarmowego
WO2018129556A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
US20120088737A2 (en) * 2009-10-02 2012-04-12 Ajinomoto Co., Inc Novel acyl guanidine derivatives
US10376481B2 (en) 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
EP2887964B1 (en) 2012-08-21 2019-07-03 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
RS58969B1 (sr) 2013-04-12 2019-08-30 Ardelyx Inc Jedinjenja koja se vezuju za nhe3 i postupci za inhibiranje transporta fosfata
MY182318A (en) 2014-07-25 2021-01-19 Taisho Pharmaceutical Co Ltd Phenyl tetrahydroisoquinoline compound substituted with heteroaryl
WO2018129557A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Inhibitors of nhe-mediated antiport
JP7292207B2 (ja) 2017-01-09 2023-06-16 アルデリックス， インコーポレイテッド 消化管障害を処置するために有用な化合物
BR112020002322A2 (pt) 2017-08-04 2020-09-01 Ardelyx, Inc. derivados de ácido glicirretinínico para o tratamento de hipercalemia
EP4234016A3 (en) 2019-02-07 2023-10-18 Ardelyx, Inc. Glycyrrhetinic acid derivatives for use in treating hyperkalemia
WO2020237096A1 (en) 2019-05-21 2020-11-26 Ardelyx, Inc. Combination for lowering serum phosphate in a patient

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3131187A (en) * 1964-04-28 Certain z-guantoino-x-aryl-quinazolines

Also Published As

Publication number Publication date
DE10019062A1 (de) 2001-10-25
KR20030011789A (ko) 2003-02-11
BR0109867A (pt) 2003-06-03
US20040224965A1 (en) 2004-11-11
CA2406161A1 (en) 2002-10-16
HUP0300909A3 (en) 2004-01-28
EP1274691A1 (de) 2003-01-15
RU2002130246A (ru) 2004-03-27
HUP0300909A2 (hu) 2003-10-28
ZA200209274B (en) 2004-02-16
SK13472002A3 (sk) 2003-02-04
MXPA02010264A (es) 2003-04-25
JP2004501082A (ja) 2004-01-15
PL356559A1 (en) 2004-06-28
NO20024997L (no) 2002-10-17
NO20024997D0 (no) 2002-10-17
CN1422260A (zh) 2003-06-04
WO2001079186A1 (de) 2001-10-25
AU2001293373A1 (en) 2001-10-30

Similar Documents

Publication Publication Date Title
AR028914A1 (es) 2-guanidino-4-aril-quinazolinas como inhibidores de nhe-3
ECSP055746A (es) Antagonistas de cgrp elegidos, procedimiento para su preparación, así como su empleo como medicamentos
ECSP055747A (es) Antagonistas de cgrp elegidos, procedimiento para su preparación, así como su empleo como medicamentos
PA8575401A1 (es) Derivados de heteroarilamida benzocondensada de tienopiridinas utiles como agentes terapeuticos, composiciones farmaceuticas que incluyen a los mismos y metrodos para su uso
BRPI0407811A (pt) composto derivados de pirazolopiridina, processo para a preparação dos mesmos, composição farmacêutica e respectivos uso
ES2187983T3 (es) Derivados 1,2,3,4-tetrahidronaftaleno sustituidos.
ECSP045229A (es) Piridinonas sustituidas como moduladores de la p38 map quinasa
AR003397A1 (es) Bifenilamidas utiles para combatir hongos nocivos para las plantas, procedimiento para prepararlas, las composiciones que las contienen,procedimiento para prepararlas y los procedimientos de aplicacion
ES2190396T3 (es) Nuevos compuestos amino-triazoles, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
AR049401A1 (es) Aza-biciclononanos
AR027437A1 (es) Derivados de purina
UY28848A1 (es) Antagonistas de cgrp seleccionados, procedimientos para su preparación, y su empleo como medicamentos
PA8551001A1 (es) Nuevos compuestos
EA200700901A1 (ru) Производные 2-амидо-4-фенилтиазола, их получение и применение в терапии
UY27424A1 (es) Agentes antidiabéticos
AR029343A1 (es) USO DE UN ANTAGONISTA DE NMDA DE BAJA AFINIDAD PARA EL TRATAMIENTO DE LA DEPRESIoN
PA8573501A1 (es) Derivados de benzoxazina y su empleo
AR046227A1 (es) Uso de tienopirimidinas en la preparacion de medicamentos para el tratamiento de tumores.
CO4950515A1 (es) Nuevos derivados de la quinolina para uso medicinal
PA8589801A1 (es) Aminoalcoxiindoles
AR041340A1 (es) Derivados de tiazolpirimidinona,proceso de preparacion y composiciones farmaceuticas que los contienen
AR041339A1 (es) Derivados de tiazolpirimidinona,proceso de preparacion y composiciones farmaceuticas que los contienen
AR030537A1 (es) Acidos quinolincarboxilicos y naftiridincarboxilico antibacterianos
AR037821A1 (es) 2-guanidin-4-heterociclilquinazolinas
AR048326A1 (es) Derivados de prolinilo

Legal Events

Date Code Title Description
FA Abandonment or withdrawal